Increased permeability of psoriatic skin to the protein, plasminogen activator inhibitor 2
| Autor: | C. J. Chase, A. R. Gould, Barry E. Chatterton, Stan Penglis, A. J. Stegink, C. L. Bunn, D. R. Smith, P. J. Sharp, J. C. Kovacs |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Chemistry
Administration Topical Dermatology General Medicine Penetration (firestop) Pharmacology Permeation medicine.disease Propylene Glycol Recombinant Proteins Iodine Radioisotopes Occlusive dressing medicine.anatomical_structure Biochemistry Permeability (electromagnetism) Psoriasis Plasminogen activator inhibitor-2 Plasminogen Activator Inhibitor 2 Solvents medicine Stratum corneum Humans Plasminogen activator Skin |
| Zdroj: | Archives of Dermatological Research. 295:249-254 |
| ISSN: | 1432-069X 0340-3696 |
| DOI: | 10.1007/s00403-003-0425-4 |
| Popis: | The penetration and permeation of the recombinant protein plasminogen activator inhibitor type 2 (PAI-2) in two formulations, one containing a penetration enhancer, into the psoriatic and uninvolved skin of eight patients with plaque-type psoriasis were investigated. Penetration and permeation of PAI-2 were measured by gamma counting and imaging following radiolabelling of a fraction of the applied PAI-2 with (123)I. The feasibility of topical delivery of drug to psoriatic plaques was confirmed by the finding that the permeability of psoriatic plaques to radiolabelled PAI-2 (P=0.007) and free (123)I (P=0.001) was approximately tenfold higher than the permeability of uninvolved skin. The addition of a penetration enhancer improved the permeation of PAI-2 into psoriatic plaques from an average of 35% to 46% (P=0.005). Occlusion decreased the permeation amount of PAI-2 from 46% to 15% due to losses on the occlusive dressing (P=0.001). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink